Latest available
Latest availableDonald Trump, Cathie Wood Bet on the Same 32 Stocks – Some Might Surprise You
President Donald Trump has disclosed over 20,000 stock trades made over the past 12 months. The trades, which the White House says Trump has no knowledge of, span a wide range of sectors and dollar amounts.
Prediction: Eli Lilly's Next Growth Wave Could Surprise Investors
Eli Lilly is growing faster than any other mega-cap drugmaker, but a pipeline drug still awaiting approval and falling U.S. prices are pulling the stock in opposite directions.
Lilly Stock Drops Lowwer Foundayo Claims an Oral Edge
Eli Lilly (LLY), the obesity and diabetes drugmaker, slipped about 0.3% to $1,181.45 at 10.15 EST time in Tuesday morning trading after it made a fresh case for
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Wall Street Breakfast Podcast: Federal Boost For Navitas
Navitas Semiconductor (NVTS) surged 12% premarket after winning a U.S. Army contract to develop next-gen silicon carbide power semiconductor technology. Eli Lilly (LLY) signals intent for larger, earlier-stage acquisitions in infectious disease, women's health, and mental health to drive future growth.
Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison
Foundayo 17.2 mg was associated with 1.5% greater weight loss and 0.3% greater A1C reduction than oral semaglutide 25 mg at 52 weeks These additional analyses build on findings of the ACHIEVE-3 head-to-head study, where Foundayo 9 mg and 17.2 mg delivered greater A1C and weight reductions than oral semaglutide 14 mg INDIANAPOLIS, Sept. 29, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), today announced results from a new analysis showing that Foundayo (orforglipron) 17.2 mg was associated with significantly greater weight loss and better blood sugar control than oral semaglutide 25 mg in adults with type 2 diabetes.
LLY's Olumiant Gets FDA Nod for Expanded Use in Pediatric Hair Loss
Eli Lilly's Olumiant wins FDA nod to treat pediatric patients 12 years of age and older with severe alopecia areata, expanding its U.S. use after strong phase III results.
Eli Lilly (LLY) is a Top-Ranked Momentum Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
He Will Switch Contractors to Help Build Eli Lilly’s $6.5 Billion Plant. Two W-2s Could Put $2,821 in Social Security Taxes Back in His Pocket
A pipefitter switching contractors during construction of a massive new pharmaceutical plant could walk away from tax season with a surprise windfall, and most workers in the same situation never even realize the money exists.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
